Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Uranium & Nuclear ETF (NLR) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance

VanEck Uranium & Nuclear ETFTrade
uniQure N.V. Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

VanEck Uranium & Nuclear ETF vs uniQure N.V. Ordinary Shares — how do they compare? VanEck Uranium & Nuclear ETF trades at $92.53 (market cap $3.37B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: VanEck Uranium & Nuclear ETF is far larger — about 2.3× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Uranium & Nuclear ETF for 9 Days and uniQure N.V. Ordinary Shares for 0 Days on average.

NLRQURE
Market Cap
$3.37B$1.45B
Volume
640,9523,323,243
Sector
Sector/ThematicHealth
52-Week High
$164.37$70.59
52-Week Low
$94.52$9.03
Typical Hold Time
9 Days0 Days
Enterprise Value
—$707.46M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Uranium & Nuclear ETF

NLR, the VanEck Uranium and Nuclear ETF, trades at $99.38, down 0.82% on the day amid a bearish technical signal. The ETF is positioned to benefit from growing demand for nuclear power driven by AI data centers and government support, as highlighted by recent news of a major Google-Constellation deal and U.S. funding for new reactors. However, key financial ratios are unavailable, and technical indicators show selling pressure with moving averages and oscillators in bearish alignment.

The outlook for NLR is mixed, with long-term catalysts from nuclear energy adoption offset by near-term volatility and lack of transparent fundamentals. Risks include sector-specific headwinds and expense ratio comparisons, but institutional interest from firms like Bank of America suggests confidence. Investors should weigh the ETF's thematic exposure against its technical weakness and opaque financial metrics.

uniQure N.V. Ordinary Shares

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NLR

No sentiment data available yet.

QURE
100% Buy0% Sell
Avg holding period · 0 Days

About VanEck Uranium & Nuclear ETF

VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.

Read more on NLR →

About uniQure N.V. Ordinary Shares

uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.

Read more on QURE →